512 related articles for article (PubMed ID: 33482338)
21. The role of JAK/STAT signaling pathway and its inhibitors in diseases.
Xin P; Xu X; Deng C; Liu S; Wang Y; Zhou X; Ma H; Wei D; Sun S
Int Immunopharmacol; 2020 Mar; 80():106210. PubMed ID: 31972425
[TBL] [Abstract][Full Text] [Related]
22. Evolving cognition of the JAK-STAT signaling pathway: autoimmune disorders and cancer.
Xue C; Yao Q; Gu X; Shi Q; Yuan X; Chu Q; Bao Z; Lu J; Li L
Signal Transduct Target Ther; 2023 May; 8(1):204. PubMed ID: 37208335
[TBL] [Abstract][Full Text] [Related]
23. Pathogenic and Therapeutic Relevance of JAK/STAT Signaling in Systemic Lupus Erythematosus: Integration of Distinct Inflammatory Pathways and the Prospect of Their Inhibition with an Oral Agent.
Alunno A; Padjen I; Fanouriakis A; Boumpas DT
Cells; 2019 Aug; 8(8):. PubMed ID: 31443172
[TBL] [Abstract][Full Text] [Related]
24. The rationale for targeting the JAK/STAT pathway in scleroderma-associated interstitial lung disease.
Talotta R
Immunotherapy; 2021 Feb; 13(3):241-256. PubMed ID: 33410346
[TBL] [Abstract][Full Text] [Related]
25. Inhibition of JAK/STAT signaling in rheumatologic disorders: The expanding spectrum.
El Jammal T; Gerfaud-Valentin M; Sève P; Jamilloux Y
Joint Bone Spine; 2020 Mar; 87(2):119-129. PubMed ID: 31521793
[TBL] [Abstract][Full Text] [Related]
26. JAK-STAT signaling pathway in the pathogenesis of atopic dermatitis: An updated review.
Huang IH; Chung WH; Wu PC; Chen CB
Front Immunol; 2022; 13():1068260. PubMed ID: 36569854
[TBL] [Abstract][Full Text] [Related]
27. Janus kinase (JAK) inhibitors in the treatment of inflammatory and neoplastic diseases.
Roskoski R
Pharmacol Res; 2016 Sep; 111():784-803. PubMed ID: 27473820
[TBL] [Abstract][Full Text] [Related]
28. JAK-inhibitors. New players in the field of immune-mediated diseases, beyond rheumatoid arthritis.
Fragoulis GE; McInnes IB; Siebert S
Rheumatology (Oxford); 2019 Feb; 58(Suppl 1):i43-i54. PubMed ID: 30806709
[TBL] [Abstract][Full Text] [Related]
29. Targeting the Janus Kinase Family in Autoimmune Skin Diseases.
Howell MD; Kuo FI; Smith PA
Front Immunol; 2019; 10():2342. PubMed ID: 31649667
[TBL] [Abstract][Full Text] [Related]
30. The Jakinibs in systemic lupus erythematosus: progress and prospects.
Mok CC
Expert Opin Investig Drugs; 2019 Jan; 28(1):85-92. PubMed ID: 30462559
[TBL] [Abstract][Full Text] [Related]
31. JAK-STAT pathway inhibitors in dermatology.
Miot HA; Criado PR; de Castro CCS; Ianhez M; Talhari C; Ramos PM
An Bras Dermatol; 2023; 98(5):656-677. PubMed ID: 37230920
[TBL] [Abstract][Full Text] [Related]
32. The Specific Roles of JAK/STAT Signaling Pathway in Sepsis.
Cai B; Cai JP; Luo YL; Chen C; Zhang S
Inflammation; 2015 Aug; 38(4):1599-608. PubMed ID: 25676437
[TBL] [Abstract][Full Text] [Related]
33. JAK-STAT signaling in cancer: From cytokines to non-coding genome.
Pencik J; Pham HT; Schmoellerl J; Javaheri T; Schlederer M; Culig Z; Merkel O; Moriggl R; Grebien F; Kenner L
Cytokine; 2016 Nov; 87():26-36. PubMed ID: 27349799
[TBL] [Abstract][Full Text] [Related]
34. Janus kinase inhibitors in dermatology: Part I. A comprehensive review.
Chapman S; Kwa M; Gold LS; Lim HW
J Am Acad Dermatol; 2022 Feb; 86(2):406-413. PubMed ID: 34246698
[TBL] [Abstract][Full Text] [Related]
35. Targeting JAK-STAT signal transduction in IBD.
Soendergaard C; Bergenheim FH; Bjerrum JT; Nielsen OH
Pharmacol Ther; 2018 Dec; 192():100-111. PubMed ID: 30048708
[TBL] [Abstract][Full Text] [Related]
36. Targeting JAK-STAT Signalling Alters PsA Synovial Fibroblast Pro-Inflammatory and Metabolic Function.
O'Brien A; Hanlon MM; Marzaioli V; Wade SC; Flynn K; Fearon U; Veale DJ
Front Immunol; 2021; 12():672461. PubMed ID: 34248953
[TBL] [Abstract][Full Text] [Related]
37. Targeting the JAK/STAT Signaling Pathway for Breast Cancer.
Shao F; Pang X; Baeg GH
Curr Med Chem; 2021; 28(25):5137-5151. PubMed ID: 33290193
[TBL] [Abstract][Full Text] [Related]
38. Phytochemicals targeting JAK/STAT pathway in the treatment of rheumatoid arthritis: Is there a future?
Kour G; Choudhary R; Anjum S; Bhagat A; Bajaj BK; Ahmed Z
Biochem Pharmacol; 2022 Mar; 197():114929. PubMed ID: 35065024
[TBL] [Abstract][Full Text] [Related]
39. Current application status and structure-activity relationship of selective and non-selective JAK inhibitors in diseases.
Li T; Yang X; Zhu J; Liu Y; Jin X; Chen G; Ye L
Int Immunopharmacol; 2023 Sep; 122():110660. PubMed ID: 37478665
[TBL] [Abstract][Full Text] [Related]
40. JAK inhibitor: Introduction.
Raychaudhuri SP; Raychaudhuri SK
Indian J Dermatol Venereol Leprol; 2023; 89(5):688-690. PubMed ID: 37609754
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
